New study sees if Real-World data can track Lecanemab's impact on families

NCT ID NCT06285448

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: HealthPartners Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether it's possible to create a registry for people with Alzheimer's who are receiving lecanemab infusions, along with their care partners. Researchers want to see if they can collect information on quality of life and caregiver burden in a real-world clinic setting. The study will enroll 20 people and their care partners at HealthPartners clinics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lecanemab
What this could lead to: If successful, this registry could help researchers understand how lecanemab affects daily life for people with Alzheimer's and their caregivers in real-world settings.
What could go wrong: This is a very small feasibility study (20 people) focused on data collection, not on proving the drug works. It may not lead to broader conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

HealthPartners Neuroscience Center

Saint Paul, Minnesota, 55130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.